Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Descriptor ID |
D017326
|
MeSH Number(s) |
E05.318.760.250.500.220 N05.715.360.775.088.500.220 N06.850.520.450.250.250.220
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2003 | 0 | 2 | 2 |
2004 | 0 | 2 | 2 |
2005 | 0 | 8 | 8 |
2006 | 2 | 4 | 6 |
2007 | 0 | 4 | 4 |
2008 | 2 | 1 | 3 |
2009 | 0 | 4 | 4 |
2010 | 0 | 8 | 8 |
2011 | 0 | 14 | 14 |
2012 | 3 | 2 | 5 |
2013 | 1 | 8 | 9 |
2014 | 1 | 6 | 7 |
2015 | 0 | 4 | 4 |
2016 | 1 | 6 | 7 |
2017 | 0 | 7 | 7 |
2018 | 1 | 5 | 6 |
2019 | 0 | 10 | 10 |
2020 | 1 | 4 | 5 |
2021 | 0 | 6 | 6 |
2022 | 0 | 6 | 6 |
2023 | 0 | 7 | 7 |
2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Prevalence of unnecessary kidney function exclusion criteria in urologic oncology clinical trials. Urol Oncol. 2024 Dec; 42(12):452.e15-452.e19.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 03 15; 190(4):477-485.
-
Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial. Addiction. 2024 04; 119(4):664-676.
-
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study. J Patient Rep Outcomes. 2023 Nov 10; 7(1):113.
-
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors. Drug Saf. 2023 11; 46(11):1049-1071.
-
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563.
-
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy. 2023 08; 15(11):787-797.
-
Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials. JCO Oncol Pract. 2023 06; 19(6):e877-e891.